Skip to content
My WebMD Sign In, Sign Up
Font Size

Medications for RA Linked to Skin Cancer

Studies Show TNF Blockers May Raise Risk of Nonmelanoma Skin Cancer
By
WebMD Health News
Reviewed by Louise Chang, MD

Oct. 19, 2009 (Philadelphia) -- People who take immune-disease drugs called TNF blockers for rheumatoid arthritis should check their bodies regularly for abnormal growths that can signal skin cancer.

That's the advice of doctors after two new studies showed that patients treated with TNF blockers have higher rates of skin cancer than patients who take other disease-modifying anti-rheumatic drugs, or DMARDs.

TNF blockers include Remicade, Enbrel, Humira, Cimzia, and Simponi. They neutralize a protein, tumor necrosis factor alpha, that is overproduced in inflammatory diseases like rheumatoid arthritis.

TNF, however, also has a normal function in the body: fighting cancer. The FDA already requires that TNF-blocking drugs carry a boxed warning of an increased risk of cancer.

The new studies link the drugs to skin cancer in particular and quantify "what we already suspected," says Eric Ruderman, MD, a rheumatologist at Northwestern University who was not involved in the new studies.

Still, experts stress that the overall risk of developing skin cancer is low and that for most patients with rheumatoid arthritis, the benefits of TNF blockers outweigh the risks.

"Yes, the findings give us pause, but TNF blockers have helped many patients ravaged by rheumatoid arthritis to become ambulatory," says Johns Hopkins rheumatologist Allan Gelber, MD.

Gelber moderated a news conference to discuss the new studies at the annual meeting of the American College of Rheumatology.

TNF Blockers and Skin Cancer

For the first study, researchers at Washington University in St. Louis combed the medical records of nearly 17,000 people with rheumatoid arthritis treated at VA hospitals around the country. About 3,000 of them were treated with TNF blockers.

Compared with people treated with other DMARDs such as Rheumatrex or Arava, people taking TNF blockers were 34% more likely to develop nonmelanoma skin cancer. The drugs were also associated with a slightly higher risk of malignant melanoma.

The longer a person was on TNF blockers, the greater their risk of nonmelanoma skin cancer, says Prabha Ranganathan, MD, a rheumatologist at Washington University.

Men, older patients, and those who took steroids to control their disease were also at increased risk of developing nonmelanoma skin cancer.

"Older patients with rheumatoid arthritis on anti-TNF therapy need to be watched closely for the development of skin cancer, especially if they are male, have been on these treatments for a long time, and have a history of other cancers," she tells WebMD.

British Study on TNF Blockers

For the second study, British researchers reviewed a national registry that tracks the progress of people with rheumatoid arthritis.

Taking a TNF-blocking drug appeared to increase the risk of developing nonmelanoma basal or squamous cell skin cancers by about 70%, compared to treatment with a traditional DMARD, but the finding could have been due to chance.

Today on WebMD

fish oil capsule
Article
senior woman holding green apple
Article
 
young women in yoga class
Video
Man with knee brace
Article
 
Lucille Ball
Slideshow
Hand bones X-ray
Article
 
prescription pills
Article
Woman massaging her neck
Quiz
 
woman roasting vegetables in oven
Slideshow
Woman rubbing shoulder
Slideshow
 
Working out with light weights
Video
arthritis
Article